Assertio to Participate in the 2022 Lake Street BIG6 Conference

LAKE FOREST, Ill., Sept. 07, 2022 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that Dan Peisert, CEO, will host investor meetings September 14, 2022 as part of the Lake Street Capital Markets Best Ideas Growth Conference (BIG6), taking place at The Yale Club in New York City.

As part of the conference event, management will host one-on-one meetings throughout the day.

For more information about scheduling a one-on-one meeting with management, please contact your Lake Street representative or Matt Kreps, Investor Relations for Assertio Holdings, at mkreps@darrowir.com.

About Assertio

Assertio Holdings, Inc. is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through business development including licensing, mergers, and acquisitions. For more information regarding Assertio Holdings, go to: https://www.assertiotx.com/.

Investor Contact:
Matt Kreps
Managing Director
Darrow Associates
Austin, TX
M: 214-597-8200
mkreps@darrowir.com

Staff

Recent Posts

Olympian Gabby Thomas Draws Crowd at Wellness Event with BetterWay(TM) Blood Testing at H-E-B SoCo

Guests had an opportunity to meet Gabby Thomas, win health-focused prizes, and learn simple ways…

2 hours ago

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

11 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

14 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

14 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

14 hours ago